A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Public ClinicalTrials.gov record NCT06973291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.
Study identification
- NCT ID
- NCT06973291
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 606 participants
Conditions and interventions
Conditions
Interventions
- Zasocitinib Drug
- Deucravacitinib Drug
- Placebo to match zasocitinib Drug
- Placebo to match deucravacitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2025 (Actual)
- Primary completion
- Apr 22, 2026 (Actual)
- Completion
- Apr 22, 2026 (Actual)
- Last update posted
- May 1, 2026
2025 – 2026
United States locations
- U.S. sites
- 31
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Johnson Dermatology | Fort Smith | Arkansas | 72916-6103 | — |
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913-6475 | — |
| Zenith Research, Inc. | Beverly Hills | California | 90212 | — |
| First OC Dermatology Research Inc. | Fountain Valley | California | 92708 | — |
| UNISON Clinical Trials (Shahram Jacobs md inc.) | Sherman Oaks | California | 91403 | — |
| Central Connecticut Dermatology, PLLC | Cromwell | Connecticut | 06416 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06511 | — |
| Direct Helpers Research Center | Hialeah | Florida | 33012 | — |
| San Marcus Research Clinic Inc | Miami Lakes | Florida | 33014 | — |
| Advanced Clinical Research Institute | Tampa | Florida | 33607-6429 | — |
| Arlington Dermatology | Rolling Meadows | Illinois | 60008-3811 | — |
| Endeavor Health Clinical Trials | Skokie | Illinois | 60077 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| Lawrence J Green, MD LLC | Rockville | Maryland | 20850 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| JDR Dermatology Research, LLC | Las Vegas | Nevada | 89145 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Markowitz Medical PLLC dba OptiSkin Medical | New York | New York | 10128 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27516 | — |
| Bexley Dermatology Research - Probity - PPDS | Bexley | Ohio | 43209 | — |
| Apex Clinical Research Center, LLC - Canton | Canton | Ohio | 44718 | — |
| Apex Clinical Research Center, LLC - Mayfield Heights | Mayfield Heights | Ohio | 44124-4005 | — |
| UPMC Department of Dermatology | Pittsburgh | Pennsylvania | 15213-3403 | — |
| Goodlettsville Dermatology Research | Goodlettsville | Tennessee | 37072 | — |
| Arlington Research Center | Arlington | Texas | 76011-3800 | — |
| Bellaire Dermatology Associates | Bellaire | Texas | 77401-3505 | — |
| The University of Texas Health Science Center at Houston (UTHSC-H) | Bellaire | Texas | 77401 | — |
| Reveal Research Institute | Dallas | Texas | 75235 | — |
| San Antonio | San Antonio | Texas | 78213-2250 | — |
| Texas Dermatology and Laser Specialists-San Antonio | San Antonio | Texas | 78218-3128 | — |
| Houston Center for Clinical Research, LLC | Sugar Land | Texas | 77479-1001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06973291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06973291 live on ClinicalTrials.gov.